Latest ArticlesEN-USSun, 04 Dec 2016 17:00:23 -0500716231
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-N8g_3S15Qk/the-math-shows-jkh-can-go-to-180-cm716231
The Math Shows JKH Can Go To $180Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-N8g_3S15Qk" height="1" width="1" alt=""/>Thu, 01 Dec 2016 15:17:28 Z2016-12-01T15:17:28Zhttp://www.nasdaq.com/article/the-math-shows-jkh-can-go-to-180-cm716231715299
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s9RvKo38FPI/charles-payne-on-biotech-biogen-inc-biib-intercept-pharmaceuticals-inc-icpt-cm715299
Charles Payne on Biotech: Biogen Inc (BIIB), Intercept Pharmaceuticals Inc (ICPT)InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips I ve been talking a lot recently about where I see opportunity after the election and looking ahead to a Donald Trump administration Today I want to talk about the potential within the biotechnology<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/s9RvKo38FPI" height="1" width="1" alt=""/>Tue, 29 Nov 2016 19:54:30 Z2016-11-29T19:54:30Zhttp://www.nasdaq.com/article/charles-payne-on-biotech-biogen-inc-biib-intercept-pharmaceuticals-inc-icpt-cm715299703939
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gPVDWikpyXQ/intercept-icpt-q3-loss-narrower-than-expected-sales-miss-cm703939
Intercept (ICPT) Q3 Loss Narrower than Expected, Sales MissIntercept Pharmaceuticals Inc ICPT posted a loss of 3 59 per share in the third quarter of 2016 narrower than the Zacks Consensus Estimate of a loss of 3 72 but wider than the year ago loss of 2 10 FindTheCompany Graphiq Quarterly revenues came in at 5 2 million<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/gPVDWikpyXQ" height="1" width="1" alt=""/>Fri, 04 Nov 2016 15:12:18 Z2016-11-04T15:12:18Zhttp://www.nasdaq.com/article/intercept-icpt-q3-loss-narrower-than-expected-sales-miss-cm703939703235
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R1vRCSaL7jw/intercept-icpt-reports-narrower-than-expected-q3-loss-cm703235
Intercept (ICPT) Reports Narrower-Than-Expected Q3 LossNew York based Intercept Pharmaceuticals Inc ICPT focused on bringing novel therapeutics to treat chronic liver diseases to market Intercept received a major boost with the FDA approval in May 2016 of its lead drug Ocaliva in combination with ursodeoxycholic UDCA for the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/R1vRCSaL7jw" height="1" width="1" alt=""/>Thu, 03 Nov 2016 14:09:36 Z2016-11-03T14:09:36Zhttp://www.nasdaq.com/article/intercept-icpt-reports-narrower-than-expected-q3-loss-cm703235703044
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LSw-3ML7FBs/earnings-reaction-history-intercept-pharm-444-follow-through-indicator-52-sensitive-cm703044
Earnings Reaction History: INTERCEPT PHARM, 44.4% Follow-Through Indicator, 5.2% SensitiveExpected Earnings Release 11 03 2016 PremarketExpected Earnings Release 11 03 2016 Premarket Avg Extended Hours Dollar Volume 24 841 175Avg Extended Hours Dollar Volume 24 841 175 INTERCEPT PHARM ICPT is due to issue its quarterly earnings report in the upcoming extended<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/LSw-3ML7FBs" height="1" width="1" alt=""/>Thu, 03 Nov 2016 11:07:33 Z2016-11-03T11:07:33Zhttp://www.nasdaq.com/article/earnings-reaction-history-intercept-pharm-444-follow-through-indicator-52-sensitive-cm703044702608
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yQAy4YrgsIE/noteworthy-wednesday-option-activity-angi-icpt-dbd-cm702608
Noteworthy Wednesday Option Activity: ANGI, ICPT, DBDLooking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Angie s List Inc Symbol ANGI where a total volume of 1 573 contracts has been traded thus far today a contract volume which is representative of approximately 157<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/yQAy4YrgsIE" height="1" width="1" alt=""/>Wed, 02 Nov 2016 17:08:17 Z2016-11-02T17:08:17Zhttp://www.nasdaq.com/article/noteworthy-wednesday-option-activity-angi-icpt-dbd-cm702608702314
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-bcqNT1wDlU/drug-stocks-q3-earnings-roster-for-nov-3-icpt-exel-akrx-cm702314
Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRXThe Q3 earnings season moves into the last leg of its reporting cycle with 332 S amp P 500 members as of Nov 1 accounting for 74 1 of the index s total market capitalization having already reported results according to the Earnings Outlook report While total earnings for these<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-bcqNT1wDlU" height="1" width="1" alt=""/>Wed, 02 Nov 2016 13:17:00 Z2016-11-02T13:17:00Zhttp://www.nasdaq.com/article/drug-stocks-q3-earnings-roster-for-nov-3-icpt-exel-akrx-cm702314701605
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sNBFeM5NHTE/intercept-icpt-q3-earnings-preview-whats-in-the-cards-cm701605
Intercept (ICPT) Q3 Earnings Preview: What's in the Cards?Intercept Pharmaceuticals Inc ICPT is scheduled to report third quarter 2016 results on Nov 3 before market opens In the last reported quarter the company recorded a positive surprise of 16 49 Let s see how things are shaping up for this announcement Factors at<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/sNBFeM5NHTE" height="1" width="1" alt=""/>Tue, 01 Nov 2016 13:16:21 Z2016-11-01T13:16:21Zhttp://www.nasdaq.com/article/intercept-icpt-q3-earnings-preview-whats-in-the-cards-cm701605700969
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uw0Tdwdxnko/40-billion-opportunity-3-biotechs-poised-to-dominate-cm700969
$40 Billion Opportunity: 3 Biotechs Poised to DominateNonalcoholic steatohepatitis NASH has been called the next hepatitis C by some Both NASH and hepatitis C are liver diseases and both represent huge markets for drugmakers working on cures While the hepatitis C treatment landscape has filled out over the past few years with<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Uw0Tdwdxnko" height="1" width="1" alt=""/>Mon, 31 Oct 2016 15:16:53 Z2016-10-31T15:16:53Zhttp://www.nasdaq.com/article/40-billion-opportunity-3-biotechs-poised-to-dominate-cm700969695825
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JQ7hEh4CwZE/vertex-vrtx-q3-earnings-whats-in-store-for-the-stock-cm695825
Vertex (VRTX) Q3 Earnings: What's in Store for the Stock?Biotech company Vertex Pharmaceuticals VRTX will be reporting third quarter 2016 results on Oct 25 after the market closes Vertex s track record is mixed with the company delivering positive surprises in three of the last four quarters and missing expectations in one The average<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/JQ7hEh4CwZE" height="1" width="1" alt=""/>Thu, 20 Oct 2016 14:52:28 Z2016-10-20T14:52:28Zhttp://www.nasdaq.com/article/vertex-vrtx-q3-earnings-whats-in-store-for-the-stock-cm695825694108
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qml6Lbl8o6I/intercept-icpt-ocaliva-wins-positive-chmp-opinion-for-pbc-cm694108
Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBCIntercept Pharmaceuticals Inc ICPT announced that that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has recommended a conditional approval of Ocaliva obeticholic acid OCA for the treatment of primary biliary cholangitis PBC Note that<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Qml6Lbl8o6I" height="1" width="1" alt=""/>Mon, 17 Oct 2016 15:42:42 Z2016-10-17T15:42:42Zhttp://www.nasdaq.com/article/intercept-icpt-ocaliva-wins-positive-chmp-opinion-for-pbc-cm69410820161017-00012
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDfF_3BNGgc/be-all-ears-for-abeo-lucentis-pfs-gets-fda-nod-xoma-effects-stock-split-20161017-00012
Be All Ears For ABEO, Lucentis PFS Gets FDA Nod, XOMA Effects Stock SplitBe All Ears For ABEO, Lucentis PFS Gets FDA Nod, XOMA Effects Stock Split<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/JDfF_3BNGgc" height="1" width="1" alt=""/>Mon, 17 Oct 2016 01:02:00 Z2016-10-17T01:02:00Zhttp://www.nasdaq.com/article/be-all-ears-for-abeo-lucentis-pfs-gets-fda-nod-xoma-effects-stock-split-20161017-0001220161014-00471
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2y_316QpLvM/intercept-pharma-gets-positive-chmp-opinion-for-ocaliva-to-treat-pbc-20161014-00471
Intercept Pharma Gets Positive CHMP Opinion For Ocaliva To Treat PBCIntercept Pharma Gets Positive CHMP Opinion For Ocaliva To Treat PBC<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/2y_316QpLvM" height="1" width="1" alt=""/>Fri, 14 Oct 2016 07:56:00 Z2016-10-14T07:56:00Zhttp://www.nasdaq.com/article/intercept-pharma-gets-positive-chmp-opinion-for-ocaliva-to-treat-pbc-20161014-00471686383
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k9Jh7zq_Hgo/nonalcoholic-steatohepatitis-whats-the-market-opportunity-and-who-are-the-major-players-cm686383
Nonalcoholic Steatohepatitis: What's The Market Opportunity And Who Are The Major Players?By Slingshot Insights BySlingshot Insights By Killian McKee Slingshot contributor By Killian McKee Slingshot contributorBy Killian McKee Slingshot contributor On September 20th Allergan AGN brought increased investor attention to the NASH market by buying two<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/k9Jh7zq_Hgo" height="1" width="1" alt=""/>Fri, 07 Oct 2016 21:44:37 Z2016-10-07T21:44:37Zhttp://www.nasdaq.com/article/nonalcoholic-steatohepatitis-whats-the-market-opportunity-and-who-are-the-major-players-cm686383687855
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4XD0NyoNVSU/notable-monday-option-activity-icpt-pg-seas-cm687855
Notable Monday Option Activity: ICPT, PG, SEASAmong the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Intercept Pharmaceuticals Inc Symbol ICPT where a total of 2 436 contracts have traded so far representing approximately 243 600 underlying shares That amounts to about 56 6<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/4XD0NyoNVSU" height="1" width="1" alt=""/>Mon, 03 Oct 2016 15:44:46 Z2016-10-03T15:44:46Zhttp://www.nasdaq.com/article/notable-monday-option-activity-icpt-pg-seas-cm687855687054
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0caJldhJxPI/analysts-forecast-10-upside-for-jkh-cm687054
Analysts Forecast 10% Upside For JKHLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/0caJldhJxPI" height="1" width="1" alt=""/>Fri, 30 Sep 2016 15:22:18 Z2016-09-30T15:22:18Zhttp://www.nasdaq.com/article/analysts-forecast-10-upside-for-jkh-cm687054686378
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qDwPZbB20h4/nonalcoholic-steatohepatitis-nash-whats-the-market-opportunity-and-who-are-the-major-players-cm686378
Nonalcoholic Steatohepatitis (NASH): What's The Market Opportunity And Who Are The Major Players?By Slingshot Insights BySlingshot Insights By Killian McKee Slingshot contributorBy Killian McKee Slingshot contributor On September 20th Allergan AGN brought increased investor attention to the NASH market by buying two treatment developers Tobira Therapeutics Inc 1 7 billion<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/qDwPZbB20h4" height="1" width="1" alt=""/>Thu, 29 Sep 2016 08:21:58 Z2016-09-29T08:21:58Zhttp://www.nasdaq.com/article/nonalcoholic-steatohepatitis-nash-whats-the-market-opportunity-and-who-are-the-major-players-cm68637820160920-01178
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cK2hLD_wDLs/stocks-close-slightly-higher-ahead-of-boj-fed-decisions--us-commentary-20160920-01178
Stocks Close Slightly Higher Ahead Of BoJ, Fed Decisions - U.S. CommentaryStocks Close Slightly Higher Ahead Of BoJ, Fed Decisions - U.S. Commentary<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/cK2hLD_wDLs" height="1" width="1" alt=""/>Tue, 20 Sep 2016 16:15:00 Z2016-09-20T16:15:00Zhttp://www.nasdaq.com/article/stocks-close-slightly-higher-ahead-of-boj-fed-decisions--us-commentary-20160920-0117820160920-00329
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2iT4R9cLbXI/stocks-continue-to-see-modest-strength-in-midday-trading--us-commentary-20160920-00329
Stocks Continue To See Modest Strength In Mid-Day Trading - U.S. CommentaryStocks Continue To See Modest Strength In Mid-Day Trading - U.S. Commentary<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/2iT4R9cLbXI" height="1" width="1" alt=""/>Tue, 20 Sep 2016 12:01:00 Z2016-09-20T12:01:00Zhttp://www.nasdaq.com/article/stocks-continue-to-see-modest-strength-in-midday-trading--us-commentary-20160920-0032920160920-01107
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aVMOZcIceCg/stocks-pull-back-off-highs-but-remain-mostly-positive--us-commentary-20160920-01107
Stocks Pull Back Off Highs But Remain Mostly Positive - U.S. CommentaryStocks Pull Back Off Highs But Remain Mostly Positive - U.S. Commentary<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/aVMOZcIceCg" height="1" width="1" alt=""/>Tue, 20 Sep 2016 10:48:00 Z2016-09-20T10:48:00Zhttp://www.nasdaq.com/article/stocks-pull-back-off-highs-but-remain-mostly-positive--us-commentary-20160920-0110720160920-00194
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iEXw1jX7wrc/intercept-pharmaceuticals-inc-icpt-has-risen-to-nearly-a-1month-high-20160920-00194
Intercept Pharmaceuticals Inc. (ICPT) Has Risen To Nearly A 1-Month HighIntercept Pharmaceuticals Inc. (ICPT) Has Risen To Nearly A 1-Month High<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/iEXw1jX7wrc" height="1" width="1" alt=""/>Tue, 20 Sep 2016 09:52:00 Z2016-09-20T09:52:00Zhttp://www.nasdaq.com/article/intercept-pharmaceuticals-inc-icpt-has-risen-to-nearly-a-1month-high-20160920-0019420160920-00338
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KICoivIhBEk/allergan-to-buy-tobira-therapeutics-in-17-billion-deal-20160920-00338
Allergan to Buy Tobira Therapeutics in $1.7 Billion DealAllergan to Buy Tobira Therapeutics in $1.7 Billion Deal<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/KICoivIhBEk" height="1" width="1" alt=""/>Tue, 20 Sep 2016 09:35:00 Z2016-09-20T09:35:00Zhttp://www.nasdaq.com/article/allergan-to-buy-tobira-therapeutics-in-17-billion-deal-20160920-00338